News & Publications - Sionna Therapeutics

Press Releases

August 13, 2024

Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis

July 16, 2024

Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie

June 3, 2024

Sionna Therapeutics Announces Appointment of Jennifer Fitzpatrick as General Counsel

March 6, 2024

Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis

January 24, 2024

Sionna Therapeutics Announces Phase 1 Initiation for SION-109 in Cystic Fibrosis

January 3, 2024

Sionna Therapeutics to Present Updates on Clinical Progress in Cystic Fibrosis at 42nd Annual J.P. Morgan Healthcare Conference

November 3, 2023

Sionna Therapeutics Presents Preclinical Data at 2023 North American Cystic Fibrosis Conference Demonstrating Series 2 NBD1 Stabilizers Normalize ΔF508-CFTR Function

October 18, 2023

Sionna Therapeutics to Present at 2023 North American Cystic Fibrosis Conference

June 8, 2023

Sionna Therapeutics Announces Presentation of Preclinical Data on NBD1 Stabilizers at 46th European Cystic Fibrosis Conference

January 5, 2023

Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference

December 7, 2022

Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis

November 14, 2022

Sionna Therapeutics Announces Appointment of Vanya Sagar as Chief People Officer

November 3, 2022

Sionna Therapeutics Presents Preclinical Data Demonstrating Restoration of ΔF508-CFTR by Stabilizing NBD1 with SION-638 in Cystic Fibrosis

October 4, 2022

Sionna Therapeutics to Present at the North American Cystic Fibrosis Conference

August 1, 2022

Sionna Therapeutics Announces Formation of Scientific Advisory Board

June 6, 2022

Sionna Therapeutics Announces Appointment of Paul Clancy to Board of Directors

April 19, 2022

Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis

Our Presentations

NACFC | November 3, 2023

Poster – Novel, Highly Potent NBD1 Stabilizing Development Candidates Enable Full ΔF508-CFTR Correction and a Path to Wild-type Function

ECFS | June 8, 2023

Poster – Novel CFTR Modulator Combinations Directly Address the ΔF508-CFTR NBD1 Stability Defect and Enable Full CFTR Correction

NACFC | November 4, 2022

Oral Presentation – Novel Modulator Combinations Address the NBD1 Stability Defect Central to ΔF508-CFTR Dysfunction and Enable Full Correction

NACFC | November 3, 2022

Poster – Novel Modulator Combinations Address the NBD1 Stability Defect Central to ΔF508-CFTR Dysfunction and Enable Full Correction

Clinical Expert Videos

Guided by Clinical Experts in Cystic Fibrosis – Sionna Therapeutics sat down with members of its Clinical Advisory Board to hear their expert perspectives on the unmet needs in Cystic Fibrosis.